Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins (Q35556348)

8 August 2017

1 reference

title

Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins (English)

1 reference

8 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S1568-9972(03)00049-1

20 March 2024

author name string

Flore Mulhaupt

2

1 reference

8 August 2017

François Mach

3

1 reference

8 August 2017

Brenda R. Kwak

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14550874

20 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14550874

20 March 2024

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S1568997203000491?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1568-9972(03)00049-1

https://api.elsevier.com/content/article/PII:S1568997203000491?httpAccept=text/plain

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1568-9972(03)00049-1

20 March 2024

1 reference

8 August 2017

2

1 reference

8 August 2017

6

1 reference

8 August 2017

332-338

1 reference

Atherosclerosis. the road ahead

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Changing concepts of atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Current perspectives on statins

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

The evolving role of statins in the management of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Direct effects of statins on cells primarily involved in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Statins and monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

The bare lymphocyte syndrome and the regulation of MHC expression

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

PROAPOPTOTIC EFFECT OF ATORVASTATIN ON STIMULATED RABBIT SMOOTH MUSCLE CELLS

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Current concepts of the pathogenesis of the acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2803%2900049-1

7 January 2021

The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells

25

1 reference

https://api.crossref.org/works/10.1016/S1568-9972(03)00049-1

Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation

20 March 2024

27

1 reference

https://api.crossref.org/works/10.1016/S1568-9972(03)00049-1

Influence of cholesterol-lowering on plasma membrane lipids and function

20 March 2024

38

1 reference

https://api.crossref.org/works/10.1016/S1568-9972(03)00049-1

Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents

20 March 2024

39

1 reference

https://api.crossref.org/works/10.1016/S1568-9972(03)00049-1

20 March 2024

Identifiers

1 reference

8 August 2017

1 reference